Plant ID: NPO20846
Plant Latin Name: Sophora japonica
Taxonomy Genus: Sophora
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
3897
Plant-of-the-World-Online:
n.a.
Abortifacient; Antibacterial; Anticholesterolemic; Antidiarrhoeal; Antiinflammatory; Antispasmodic; Diuretic; Emetic; Emollient; Febrifuge; Hypotensive; Purgative; Skin; Styptic; Tonic
China
TSHR; NPSR1; | |
FFAR1; FFAR4; | |
ACHE; | |
BLM; ALOX12; HSD17B2; HSD17B10; ALOX15; NOX4; ALDH1A1; USP2; AOX1; APEX1; POLB; | |
AURKB; MET; AXL; FLT3; CDK1; EGFR; PIM1; KDR; IGF1R; | |
CA2; CA12; CA9; CA14; CA7; CA4; | |
ESR2; ESR1; | |
NR1H4; | |
ESRRB; ESRRA; | |
TYR; | |
AHR; | |
SLCO1B1; | |
LMNA; FABP3; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.401E-13 | 2.787E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.574E-10 | 1.245E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.875E-10 | 1.344E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.713E-09 | 3.369E-06 | ALOX12, ALOX15, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.848E-09 | 4.829E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.184E-08 | 1.399E-05 | CA12, CA2, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.635E-07 | 6.806E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.765E-07 | 7.119E-05 | AHR, ESR1, ESR2, ESRRA, ESRRB, NR1H4, PIM1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.411E-07 | 8.606E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | Unclassified; | GO:0004872; receptor activity | 2.792E-07 | 9.498E-05 | AHR, AXL, EGFR, ESR1, ESR2, ESRRA, ESRRB, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, NR1H4, TSHR |
MF | GO:0005488; binding | GO:0020037; heme binding | 5.673E-07 | 1.740E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.569E-06 | 4.269E-04 | APEX1, BLM, CYP1A1, CYP1B1, EGFR, ESR1, FLT3, NOX4 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.847E-06 | 4.787E-04 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.094E-06 | 5.242E-04 | CDK1, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.372E-06 | 5.740E-04 | BLM, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 3.943E-06 | 8.672E-04 | ALOX12, AURKB, AXL, CDK1, EGFR, FFAR4, IGF1R, KDR, LMNA, NR1H4, PIM1 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.002E-06 | 1.037E-03 | CA2, CA4, CA9, EGFR, SLCO1B1, TSHR |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.548E-06 | 1.069E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.548E-06 | 1.069E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.548E-06 | 1.069E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.548E-06 | 1.069E-03 | ALOX12, ALOX15 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.330E-05 | 2.228E-03 | APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.404E-05 | 2.334E-03 | ESR1, ESR2, ESRRA, ESRRB, NR1H4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.662E-05 | 2.622E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.662E-05 | 2.622E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.662E-05 | 2.622E-03 | ALOX12, ALOX15 |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.721E-05 | 2.697E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.165E-05 | 3.297E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 3.090E-05 | 4.485E-03 | ACHE, ALDH1A1, AOX1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, EGFR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 3.186E-05 | 4.594E-03 | AXL, CDK1, EGFR, FLT3 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.319E-05 | 4.633E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.319E-05 | 4.633E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.319E-05 | 4.633E-03 | CYP1A2, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 3.816E-05 | 5.258E-03 | APEX1, BLM, EGFR, IGF1R, NOX4, NR1H4, TSHR |
MF | GO:0005488; binding | GO:0042562; hormone binding | 4.949E-05 | 6.612E-03 | ACHE, ALDH1A1, EGFR, IGF1R |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.523E-05 | 7.159E-03 | ALOX12, ALOX15 |
BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 5.797E-05 | 7.425E-03 | AURKB, BLM, EGFR, NOX4, POLB, TYR, USP2 |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 6.511E-05 | 8.243E-03 | ACHE, ALOX15, CDK1, CYP1A1, EGFR |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.182E-05 | 8.988E-03 | CYP19A1, CYP1A1, CYP2C9 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.281E-12 | 1.281E-10 | CA12, CA2, CA4, CA7, CA9, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.009E-07 | 5.045E-06 | HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.152E-07 | 7.175E-06 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.834E-07 | 9.584E-06 | CYP2C9, CYP1A2, ALDH1A1, CYP1A1, AOX1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.106E-06 | 4.213E-05 | CYP1A2, CYP1A1, AOX1, CYP1B1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.373E-05 | 3.956E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 8.806E-05 | 9.785E-04 | CYP2C9, HSD17B2, CYP1A2, ALOX15, ALDH1A1, CYP1A1, AOX1, ALOX12, TYR, CYP19A1, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.002E-04 | 1.002E-03 | KDR, ESR1, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.757E-05 | 4.987E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.990E-05 | 4.987E-04 | CYP2C9, CYP1A2, ALOX15 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.916E-04 | 3.560E-03 | CYP2C9, ALOX15, ALOX12 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.921E-04 | 3.889E-03 | FLT3, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.833E-04 | 3.889E-03 | MET, EGFR, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 5.364E-04 | 3.889E-03 | CYP2C9, CYP1A2, AOX1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.183E-03 | 6.958E-03 | KDR, MET, EGFR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 6.584E-04 | 4.115E-03 | MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.389E-03 | 7.310E-03 | KDR, MET, EGFR, IGF1R |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 5.833E-04 | 3.889E-03 | SLCO1B1, CA2, NR1H4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.815E-03 | 8.644E-03 | KDR, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.530E-03 | 7.652E-03 | ESR1, EGFR, ESR2 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.178E-03 | 9.900E-03 | CYP2C9, ALOX15, ALOX12 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.270E-03 | 7.054E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; TYR; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; EGFR; CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; FFAR1; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; EGFR; CYP19A1; CA9; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; FLT3; ACHE; EGFR; CA9; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
NA: NA | Menopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; CA9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
NA: NA | HIV infections | NA | AHR; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
NA: NA | Edema | NA | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |